Evolus ROE 2016-2024 | EOLS
Current and historical return on equity (ROE) values for Evolus (EOLS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Evolus ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2024-12-31 | $-0.05B | $0.01B | -408.16% |
| 2024-09-30 | $-0.06B | $0.01B | -1000.00% |
| 2024-06-30 | $-0.05B | $0.02B | 7066.67% |
| 2024-03-31 | $-0.06B | $0.02B | 827.59% |
| 2023-12-31 | $-0.06B | $-0.02B | 620.00% |
| 2023-09-30 | $-0.06B | $-0.02B | 25200.00% |
| 2023-06-30 | $-0.07B | $-0.01B | -561.70% |
| 2023-03-31 | $-0.07B | $0.01B | -281.19% |
| 2022-12-31 | $-0.07B | $0.02B | -183.85% |
| 2022-09-30 | $-0.08B | $0.03B | -140.44% |
| 2022-06-30 | $-0.08B | $0.05B | -106.48% |
| 2022-03-31 | $-0.07B | $0.07B | -80.68% |
| 2021-12-31 | $-0.05B | $0.08B | -61.04% |
| 2021-09-30 | $-0.14B | $0.10B | -366.01% |
| 2021-06-30 | $-0.13B | $0.11B | -580.22% |
| 2021-03-31 | $-0.14B | $0.02B | -1889.66% |
| 2020-12-31 | $-0.16B | $-0.07B | -944.93% |
| 2020-09-30 | $-0.07B | $0.04B | -121.27% |
| 2020-06-30 | $-0.08B | $0.04B | -163.55% |
| 2020-03-31 | $-0.10B | $0.06B | -200.00% |
| 2019-12-31 | $-0.09B | $0.08B | -171.70% |
| 2019-09-30 | $-0.09B | $0.02B | -162.21% |
| 2019-06-30 | $-0.07B | $0.04B | -98.98% |
| 2019-03-31 | $-0.05B | $0.08B | -69.86% |
| 2018-12-31 | $-0.05B | $0.08B | -68.40% |
| 2018-09-30 | $-0.03B | $0.10B | -110.09% |
| 2018-06-30 | $-0.02B | $0.04B | -600.00% |
| 2018-03-31 | $-0.01B | $0.05B | 116.67% |
| 2017-12-31 | $-0.01B | $-0.08B | 26.32% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.779B | $0.266B |
| Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. | |||